Testosterone replacement therapy and its relationship with hyperestrogenism and obesity. Problems of laboratory diagnostics of hyperestrogenism
https://doi.org/10.14341/probl12742
Abstract
Testosterone replacement therapy (TRT) is one of the most effective and common treatments for testosterone deficiency today. It is often prescribed, focusing only on the level of testosterone and the presence of patient complaints about a decrease in sexual function. Quite rarely, doctors additionally assess the level of estradiol and, as a consequence, the initial presence of a symptom of hyperestrogenism. One of the likely consequences of the appointment of TRT may be an excess of estradiol, the excess formation of which is associated with the enzyme aromatase, which converts testosterone into estradiol. Despite the availability of laboratory determination of the level of estradiol, the result may not always coincide with the clinical picture, one of the reasons is the difference in the methods for determining the level of estradiol in each laboratory, there is no single standard or «reference» today. This article describes the evolution of TRT, and also focuses on the variability of estradiol levels from laboratory to laboratory, and explains in detail why the assessment of estradiol over time should be carried out in only one laboratory. A systematic literature search was carried out in the databases Medline, Scopus, Web of Science and Elibrary, CyberLeninka.
The purpose of our review was the need to engage the attention of specialists to the problem of hyperestrogenism, the not always justified prescription of TRT in patients with obesity, hypogonadism and hyperestrogenism, as well as to the problem of laboratory diagnosis of hyperestrogenism, which is acute not only in our country, but all over the world.
About the Authors
I. I. GolodnikovRussian Medical Academy of Continuing Professional Education
Russian Federation
Ivan I. Golodnikov
2/1 building 1 Barrikadnaja str., 125993, Moscow
Z. Sh. Pavlova
Russian Federation
Zukhra Sh. Pavlova
Moscow
A. A. Kamalov
Medical Scientific-Educational Center of Lomonosov Moscow State University
Russian Federation
Armais A. Kamalov, MD, PhD, Professor
Moscow
References
1. Pavlova ZS, Golodnikov II. Obesity = inflammation. Pathogenesis. How does this threaten men? Medical Herald of the South of Russia. 2020;11(4):6-23. (In Russ.).dоi: https://doi.org/10.21886/2219-8075-2020-11-4
2. Galimov ShN, Bozhedomov VA, Galimova EF, et al. Muzhskoe besplodie. Molekulyarnye i immunologicheskie aspekty. Moscow: GEOTAR-Media; 2020. (In Russ.).
3. Grossmann M. Hypogonadism and male obesity: Focus on unresolved questions. Clinical Endocrinology. 2018;89(1):11-21. dоi: https://doi.org/10.1111/cen.13723
4. Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. dоi: https://doi.org/10.1056/NEJMoa0911101
5. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of androgen defi y in late-onset hypogonadism: results from the European Male Aging Study (EMAS). The Journal of clinical endocrinology and metabolism. 2012;97(5):1508-1516. https://doi.org/10.1210/jc.2011-2513
6. Agarwal PK, Singh P, Chowdhury S, et al. A study to evaluate the prevalence of hypogonadism in Indian males with Type-2 diabetes mellitus. Indian J Endocrinol Metab. 2017;21(1):64-70. https://doi.org/10.4103/2230-8210.196008
7. Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295(11):1288-1299. dоi: https://doi.org/10.1001/jama.295.11.1288
8. Ametov AS, Pashkova EYu. Evolution of testosterone replacement therapy. New forms — new possibilities. Endocrinology: news, opinions, training. 2017;(2):55-65. (In Russ.).
9. Mitchell R, Hollis S, Rothwell C, et al. Age related changes in the pituitary-testicular axis in normal men; lower serum testosterone results from decreased bioactive LH drive. Clin Endocrinol (Oxf ). 1995;42(5):501-507. https://doi.org/10.1111/j.1365-2265.1995.tb02669.x
10. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. https://doi.org/10.1001/jama.2013.280386
11. Finkle WD, Greenland S, Ridgeway GK, et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLOS ONE. 2014;9(1):e85805. https://doi.org/10.1371/journal.pone.0085805
12. FDA. Testosterone products: drug safety communication. FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke [Internet]. Accessed August 15, 2020. Available from: https://www.fda.gov/Safety/MedWatch/ SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm436280.htm
13. Nguyen CP, Hirsch MS, Moeny D, et al. Testosterone and «Age-Related Hypogonadism» FDA Concerns. N Engl J Med. 2015;373(8):689-691. https://doi.org/10.1056/NEJMp1506632
14. EMA. PRAC review does not confirm increase in heart problem with testosterone medicines. 2014 [Internet]. Accessed August 18, 2020. Available from: https://www.ema.europa.eu/en/documents/press- release/prac-review-does-not-confirm-increase-heart-problems- testosterone-medicines_en.pdf
15. Snyder P, Bhasin S, Cunningham G, et al. Effects of Testosterone Treatment in Older Men. The New England journal of medicine. 2016;374:611-624. https://doi.org/10.1056/NEJMoa1506119
16. Rozhivanov RV, Yashina YuN. Aspects of androgen replacement therapy for the treatment of hypogonadism in men with diabetes and metabolic syndrome. Obesity and metabolism. 2015;12(1):11-14. (In Russ.). dоi: https://doi.org/10.14341/omet2015111-14
17. Haider A, Yassin A, Doros G, et al. Effects of long-term testosterone therapy on patients with «diabesity»: results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol. 2014;2014:683515. https://doi.org/10.1155/2014/683515
18. Corona G, Rastrelli G, Morgentaler A, et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. Eur Urol. 2017;72(6):1000-1011. https://doi.org/10.1016/j.eururo.2017.03.032
19. Saad F, Doros G, Haider KS, et al. Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study. Int J Obes (Lond). 2020;44(6):1264-1278. https://doi.org/10.1038/s41366-019-0517-7
20. Traish A. Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return? Investig Clin Urol. 2016;57(6):384-400. https://doi.org/10.4111/icu.2016.57.6.384
21. Busnelli A, Somigliana E, Vercellini P. ‘Forever Young’-Testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises. Hum Reprod. 2017;32(4):719-724. https://doi.org/10.1093/humrep/dex032
22. Jia H, Sullivan CT, McCoy SC, et al. Review of health risks of low testosterone and testosterone administration. World J Clin Cases. 2015;3(4):338-344. https://doi.org/10.12998/wjcc.v3.i4.338
23. Lapauw B, Kaufman JM. Management of endocrine disease: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. Eur J Endocrinol. 2020;183(6):R167-183. https://doi.org/10.1530/eje-20-0394
24. Dedov II, Melnichenko GA, Fadeev VV. Endocrinology. Moscow: GEOTAR-Media; 2007. (In Russ.).
25. Dedov II, Melnichenko GA, Rozhivanov RV, et al. Recommendations for the diagnosis and treatment of hypogonadism (testosterone deficiency) in men. Project. Problems of Endocrinology. 2015;61(5):60-71. (In Russ.).
26. Ho CH, Jaw FS, Wu CC, et al. The prevalence and the risk factors of testosterone deficiency in newly diagnosed and previously known type 2 diabetic men. J Sex Med. 2015;12(2):389-397. https://doi.org/10.1111/jsm.12777
27. Cattabiani C, Basaria S, Ceda GP, et al. Relationship between testosterone deficiency and cardiovascular risk and mortality in adult men. J Endocrinol Invest. 2012;35(1):104-120. https://doi.org/10.3275/8061
28. Key TJ, Appleby PN, Reeves GK, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709-722. https://doi.org/10.1038/bjc.2011.254
29. Chadid S, Barber JR, Rohrmann S, et al. Age-Specific Serum Total and Free Estradiol Concentrations in Healthy Men in US Nationally Representative Samples. J Endocr Soc. 2019;3(10):1825-1836. https://doi.org/10.1210/js.2019-00178
30. Lee DM, Tajar A, Pye SR, et al. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol. 2012;166(1):77-85. https://doi.org/10.1530/eje-11-0743
31. Reddy RG, Aung T, Karavitaki N, et al. Opioid induced hypogonadism. BMJ. 2010;341:c4462. https://doi.org/10.1136/bmj.c4462
32. Rey RA, Grinspon RP. Normal male sexual differentiation and aetiology of disorders of sex development. Best Pract Res Clin Endocrinol Metab. 2011;25(2):221-238. https://doi.org/10.1016/j.beem.2010.08.013
33. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest. 2005;28(S3):14-22.
34. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. The Journal of clinical endocrinology and metabolism. 2011;96(8):2430-2439. https://doi.org/10.1210/jc.2010-3012
35. Missmer SA, Eliassen AH, Barbieri RL, et al. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96(24):1856-1865. https://doi.org/10.1093/jnci/djh336
36. Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. The Journal of rheumatology. 2004;31(3):419-421.
37. Castagnetta LA, Carruba G, Granata OM, et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. The Journal of rheumatology. 2003;30(12):2597-2605.
38. MacDonald AA, Herbison GP, Showell M, et al. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with metaanalysis. Human reproduction update. 2010;16(3):293-311. https://doi.org/10.1093/humupd/dmp047
39. Schneider G, Kirschner MA, Berkowitz R, et al. Increased estrogen production in obese men. The Journal of clinical endocrinology and metabolism. 1979;48(4):633-638. https://doi.org/10.1210/jcem-48-4-633
40. Pavlova ZSh, Kamalov AA, Golodnikov II. Male hyperestrogenism. Artificial problem or existing reality? Are aromatase inhibitors effective and safe? Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(4):47-58. (In Russ.). https://doi.org/10.33029/2304-9529-2020-9-4-47-58
41. Kamalov AA, Pavlova ZSh, Gostry AV, et al. Estrogen metabolites and their pathogenetic role in prostate cancer (review). Tekhnologii zhivyh sistem. 2016;13(1):5-16. (In Russ.).
42. Basu A, Seth S, Arora K, et al. Evaluating estradiol levels in male patients with colorectal carcinoma. Journal of clinical and diagnostic research. 2015;9(1):8-10. https://doi.org/10.7860/jcdr/2015/10508.5397
43. Jankowska EA, Rozentryt P, Ponikowska B, et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301(18):1892-1901. https://doi.org/10.1001/jama.2009.639
44. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth. Cancer Res. 2008;68(11):4447-4454. https://doi.org/10.1158/0008-5472.CAN-08-0249
45. Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019;7(6):778-793. https://doi.org/10.1111/andr.12636
46. Ghanim H, Dhindsa S, Abuaysheh S, et al. Diminished androgen and estrogen receptors and aromatase levels in hypogonadal diabetic men: reversal with testosterone. Eur J Endocrinol. 2018;178(3):277-283. https://doi.org/10.1530/eje-17-0673
47. Butaney M, Thirumavalavan N, Balasubramanian A, et al. Treatment of Estrogen Levels in the Management of Hypogonadism: An Anonymous Survey of ISSM Members. Urology. 2020;139:104-109. https://doi.org/10.1016/j.urology.2020.01.032
48. Vesper HW, Botelho JC, Vidal ML, et al. High variability in serum estradiol measurements in men and women. Steroids. 2014;82:7-13. https://doi.org/10.1016/j.steroids.2013.12.005
49. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12(4):1071-1082. https://doi.org/10.1677/erc.1.01038
50. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616. https://doi.org/10.1093/jnci/94.8.606
51. Zhang X, Tworoger SS, Eliassen AH, et al.. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Res Treat. 2013;137(3):883-892. https://doi.org/10.1007/s10549-012-2391-z
Supplementary files
|
1. Рисунок 1. Схема стероидогенеза. | |
Subject | ||
Type | Исследовательские инструменты | |
View
(217KB)
|
Indexing metadata ▾ |
Review
For citations:
Golodnikov I.I., Pavlova Z.Sh., Kamalov A.A. Testosterone replacement therapy and its relationship with hyperestrogenism and obesity. Problems of laboratory diagnostics of hyperestrogenism. Problems of Endocrinology. 2022;68(1):101-108. (In Russ.) https://doi.org/10.14341/probl12742

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).